Noun
paclitaxel (uncountable)
(pharmacology) A taxane antineoplastic drug C47H51NO14 originally isolated from the bark of the Pacific yew, Taxus brevifolia, but now typically derived as a semisynthetic product of the English yew; it interferes with microtubule function and inhibits cell division, and is used in the treatment of some cancers, especially those of the breast and ovary.
Allergies to drugs such as cyclosporine, teniposide and drugs containing polyoxyethylated castor oil may indicate increased risk of adverse reactions to paclitaxel. Source: Internet
As noted, by 1992 extensive efforts were underway to accomplish the total synthesis of paclitaxel, efforts motivated by the desire to generate new chemical understanding rather than to achieve practical commercial production. Source: Internet
In general, in vitro assays involving microtubules, such as motility assays, rely on paclitaxel to maintain microtubule integrity in the absence of the various nucleating factors and other stabilizing elements found in the cell. Source: Internet
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Source: Internet
From 1967 to 1993, almost all paclitaxel produced was derived from bark from the Pacific yew, the harvesting of which kills the tree in the process. Source: Internet
In September 2001, NICE recommended paclitaxel should be available for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. Source: Internet